Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2017

Open Access 01-09-2017 | Erratum

Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

Authors: R. Vera, A. Ferrández, C. J. Ferrer, C. Flores, C. Joaquín, S. López, T. Martín, E. Martín, M. Marzo, A. Sarrión, E. Vaquero, A. Zapatero, J. Aparicio

Published in: Clinical and Translational Oncology | Issue 9/2017

Login to get access

Excerpt

The article Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies, written by R. Vera, A. Ferrández, C. J. Ferrer, C. Flores, C. Joaquín, S. López, T. Martín, E. Martín, M. Marzo, A. Sarrión, E. Vaquero, A. Zapatero, J. Aparicio, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 19 January 2017 without open access. …
Metadata
Title
Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies
Authors
R. Vera
A. Ferrández
C. J. Ferrer
C. Flores
C. Joaquín
S. López
T. Martín
E. Martín
M. Marzo
A. Sarrión
E. Vaquero
A. Zapatero
J. Aparicio
Publication date
01-09-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1636-z

Other articles of this Issue 9/2017

Clinical and Translational Oncology 9/2017 Go to the issue

Research Article

MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1

Research Article

Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer

Review Article

The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia

Research Article

Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer

Review Article

Role of TIM-3 in ovarian cancer

Research Article

Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits